Search

Displaying results 2211 - 2220 of 10000 in total
  1. Target

    Diamine oxidase [copper-containing]

    go.drugbank.com/bio_entities/BE0000351
    TargetEnzymeHumans

    Catalyzes the oxidative deamination of primary amines to the corresponding aldehydes with the concomitant production of hydrogen peroxide and ammonia (PubMed:12072962, PubMed:19764817, PubMed:239684, PubMed:8144586). Its preferred substr...

    Polypeptides: Diamine oxidase [copper-containing]Synonyms: Amine oxidase copper domain-containing protein 1
  2. Target

    Copper transport protein ATOX1

    go.drugbank.com/bio_entities/BE0002833
    TargetCarrierHumans

    Multifunctional copper-sensing protein that operates both as a cytosolic copper chaperone and as a copper-dependent transcription factor. … In the cytosol, transfers copper to the copper-transporting ATPase ATP7A at the trans-Golgi network, which is required for activation of secretory copper enzymes including lysyl oxidase (LOX) and SOD3.

    Polypeptides: Copper transport protein ATOX1
  3. Target

    Copper-transporting ATPase 1

    go.drugbank.com/bio_entities/BE0003666
    TransporterHumans

    ATP-driven copper (Cu(+)) ion pump that plays an important role in intracellular copper ion homeostasis (PubMed:10419525, PubMed:11092760, PubMed:28389643). … In the melanosomes of pigmented cells, provides copper cofactor to TYR to form an active TYR holoenzyme for melanin biosynthesis (By similarity)

    Polypeptides: Copper-transporting ATPase 1Synonyms: Copper pump 1
  4. Drug

    Pegloticase

    go.drugbank.com/drugs/DB09208
    ApprovedInvestigational

    [L42425] Pegloticase was approved by the FDA in 2014, and in 2022, the drug label included the co-administration of pegloticase and methotrexate.[L42425] … [A249980] The PEG group also gives pegloticase a lower potential to induce an immune response.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Tetrachlorodecaoxide

    go.drugbank.com/drugs/DB05389
    Approved

    The Corporation has commenced a Phase II clinical trial in an effort to demonstrate the efficacy of WF10 in combination with Xeloda (capecitabine) in the treatment of pancreatic cancer. … The Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the

    Categories: Compounds used in a research, industrial, or household settingProducts: IMMUNOKINE (WF 10 I.V. SOLUTION)
  6. Drug

    Pixofisiran

    go.drugbank.com/drugs/DB17294
    Experimental

    Synonyms: Rna, (a-g-a-a-g-u-u-g-g-c-a-u-g-g-u-a-g-c-c-c-u-u-g-g-g), complex with rna (c-c-c-a-a-g-g-g-c-u-a-c-c-a-u-g-c-c-a-a-c-u-u-c-u) (1:1)
  7. Drug

    Vorapaxar

    go.drugbank.com/drugs/DB09030
    Approved

    of myocardial infarction (MI) or with peripheral arterial disease (PAD). … By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.

    Synonyms: Carbamic acid, N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester, Ethyl N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f]isobenzofuran-7-yl]carbamate
  8. Drug

    Icotrokinra

    go.drugbank.com/drugs/DB21724
    ApprovedInvestigational

    Icotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist. … [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108]

  9. Drug

    Rimantadine

    go.drugbank.com/drugs/DB00478
    Approved

    An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.

    Categories: M2 Protein Inhibitors, Influenza A M2 Protein Inhibitor
  10. Drug

    Voclosporin

    go.drugbank.com/drugs/DB11693
    ApprovedInvestigational

    Within 10 years of being diagnosed with SLE, 5-20% of those suffering from LN develop end-stage kidney disease, a fatal condition. … [L31208] Voclosporin has demonstrated a more stable pharmacokinetic and pharmacodynamic relationship than cyclosporine, a higher potency than cyclosporine, and an improved metabolic profile when compared